Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients
- PMID: 23686698
- PMCID: PMC3760979
- DOI: 10.1002/hep.26465
Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients
Abstract
The characteristics of nonalcoholic fatty liver disease (NAFLD) in elderly patients are unknown. Therefore, we aimed to examine the differences between elderly and nonelderly patients with NAFLD and to identify determinants of nonalcoholic steatohepatitis (NASH) and advanced fibrosis (bridging fibrosis or cirrhosis) in elderly patients. This is a cross-sectional analysis of adult participants who were prospectively enrolled in the NASH Clinical Research Network studies. Participants were included based on availability of the centrally reviewed liver histology data within 1 year of enrollment, resulting in 61 elderly (age ≥65 years) and 735 nonelderly (18-64 years) participants. The main outcomes were the presence of NASH and advanced fibrosis. Compared to nonelderly patients with NAFLD, elderly patients had a higher prevalence of NASH (56% versus 72%, P = 0.02), and advanced fibrosis (25% versus 44%, P = 0.002). Compared to nonelderly patients with NASH, elderly patients with NASH had higher rates of advanced fibrosis (35% versus 52%, P = 0.03), as well as other features of severe liver disease including the presence of ballooning degeneration, acidophil bodies, megamitochondria, and Mallory-Denk bodies (P ≤ 0.05 for each). In multiple logistic regression analyses, independent determinants of NASH in elderly patients included higher aspartate aminotransferase (AST) (odds ratio [OR] = 1.12, P = 0.007) and lower platelets (OR = 0.98, P = 0.02); and independent determinants of advanced fibrosis included higher AST (OR = 1.08, P = 0.007), lower alanine aminotransferase value (OR = 0.91, P = 0.002), and an increased odds of having low high-density lipoprotein (OR = 8.35, P = 0.02).
Conclusion: Elderly patients are more likely to have NASH and advanced fibrosis than nonelderly patients with NAFLD. Liver biopsy may be considered in elderly patients and treatment should be initiated in those with NASH and advanced fibrosis.
© 2013 by the American Association for the Study of Liver Diseases.
Conflict of interest statement
Figures
References
-
- Kim WR, Brown RS, Jr, Terrault NA, et al. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227–42. - PubMed
-
- Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. The American journal of gastroenterology. 2003;98:960–7. - PubMed
-
- Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–31. - PubMed
-
- Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. Journal of hepatology. 2010;53:372–84. - PubMed
-
- Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95. - PubMed
Publication types
MeSH terms
Grants and funding
- UL1RR02501401/RR/NCRR NIH HHS/United States
- U01 DK061732/DK/NIDDK NIH HHS/United States
- U01DK061731/DK/NIDDK NIH HHS/United States
- K23DK090303/DK/NIDDK NIH HHS/United States
- U01DK061718/DK/NIDDK NIH HHS/United States
- UL1 TR000058/TR/NCATS NIH HHS/United States
- U01DK061728/DK/NIDDK NIH HHS/United States
- U01 DK061730/DK/NIDDK NIH HHS/United States
- U01 DK061728/DK/NIDDK NIH HHS/United States
- U01 DK061734/DK/NIDDK NIH HHS/United States
- M01RR020359/RR/NCRR NIH HHS/United States
- M01RR000827/RR/NCRR NIH HHS/United States
- U01DK061738/DK/NIDDK NIH HHS/United States
- U01 DK061737/DK/NIDDK NIH HHS/United States
- U01 DK061713/DK/NIDDK NIH HHS/United States
- UL1 RR024989/RR/NCRR NIH HHS/United States
- U01DK061737/DK/NIDDK NIH HHS/United States
- P30 DK026743/DK/NIDDK NIH HHS/United States
- U01 DK061731/DK/NIDDK NIH HHS/United States
- UL1RR02413101/RR/NCRR NIH HHS/United States
- U01 DK061718/DK/NIDDK NIH HHS/United States
- M01RR000065/RR/NCRR NIH HHS/United States
- U01DK061732/DK/NIDDK NIH HHS/United States
- M01 RR000750/RR/NCRR NIH HHS/United States
- M01 RR000065/RR/NCRR NIH HHS/United States
- UL1 TR000439/TR/NCATS NIH HHS/United States
- T32 DK007202/DK/NIDDK NIH HHS/United States
- K23 DK090303/DK/NIDDK NIH HHS/United States
- U01 DK061738/DK/NIDDK NIH HHS/United States
- UL1RR024989/RR/NCRR NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- M01 RR000827/RR/NCRR NIH HHS/United States
- U01DK061734/DK/NIDDK NIH HHS/United States
- M01 RR020359/RR/NCRR NIH HHS/United States
- M01RR000750/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical